COVID-19 Impact Analysis on Autogenous Vaccines Market
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the autogenous vaccines market. In addition, complete analysis of changes on the global autogenous vaccines market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. During COVID-19 pandemic, global autogenous vaccines market was more or less affected due to supply chain distribution, declining demand for autogenous vaccines from various end User livestock farming companies, veterinary clinics and hospitals, veterinary research institutes which has certainly affected the market growth to major extend. However, post COVID-19 the market has witnessed the rising new growth opportunities and is expected to have emerging demand in upcoming years.
Market Overview- Global Autogenous Vaccines Market
Market Drivers
The key factor driving the market growth are rise in number of livestock farms and cultures along with the rise in number of livestock diseases in poultry farms, aquaculture etc. globally alongwith regulating and controlling programmes for animal diseases that will contribute in the market growth. For instance, livestock diseases are a serious issue when it comes to livestock production systems that not only affects the quality and total production but also increase the overall cost for the treatment of livestock diseases in a herd population. There are a number of diseases that affect livestock animals like Swine flu, Bird Flu, Brucellosis, Rabies etc. These diseases can be prevented by given them custom vaccines that not only treat a particular flock disease but also treat them by increasing their passive immune response to that particular type of disease. Furthermore, growing demand fish vaccine in global countries are some of the major factors propelling the demand for market.
Market Opportunity
The global autogenous vaccines market is expected to witness increasing new growth opportunities for market with growing collaborations of autogenous vaccines-based product manufacturer and retailers to increase the net total distribution of autogenous vaccines globally alongwith their awareness that has specifically accelerated the demand for the global market across the globe. Furthermore, increasing opportunities with emerging livestock farming companies, veterinary clinics and hospitals for autogenous vaccines products production is expected to be observed as the major growth opportunities for market. Likewise, increasing health consciousness for various End User consumer and expenditure is expected to drive the market.
Market Restrains
The major restraining factor for the global autogenous vaccines market is high cost of vaccine development & stringent regulatory framework for vaccine production &. The different advantages of Autogenous vaccines are mostly observed in various end user industries as they are the sole user for that. Vaccine production involves high cost of for research and development activities that needs to be carried out for manufacturing, Quality check and validating before approval from clinical trials. It also requires a proper technique for manufacturing an autogenous vaccine that is difficult to acquire and so technology transfer require a strong cooperative relation between the partners. All of these factors create barrier of entry into vaccine production. These factors are expected to restrain the market growth over the forecast period (2022-2028).
Market Growth Challenges
The major growth challenge for the market is limited use, proper supply chain & lack of awareness among peoples for autogenous vaccines. Autogenous vaccines are known for their limited use. With the increasing demand for normal livestock vaccines, peoples are not knowing very much about the use of autogenous vaccines than normal livestock vaccines that is one of the restraining factors for market growth of autogenous vaccines.
Cumulative Growth Analysis
The report provides in-depth analysis of global autogenous vaccines market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various autogenous vaccines in various End Users has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2021-2028.
Market Segmental Overview
The global autogenous vaccines market comprises of different market segment like Strain Type, End User and geography.
Autogenous Vaccines Market by Strain Type
The strain type used for manufacturing global autogenous vaccines market are bacterial and viral. Bacteria are commonly used for manufacturing autogenous vaccines due their high stability of cultures in vitro labs and incubators. Different strain types of bacteria like haemophilus, mycoplasma, salmonella & staphylococcus etc. have been in use used for manufacturing autogenous vaccines. Bacteria are isolated from a target organism using different isolation methods cultured in lab, inactivated and then introduced again in the host body in vaccine form. Besides bacteria, viruses are also used as a strain type for autogenous vaccines but due to their high instability in invitro cultures due to rapid changes in their epitope, are not used widely for the manufacture of autogenous vaccines. Thus, bacterial strain type is likely to contribute healthy growth in the market during the estimated time period and will dominate in the forecast period.
Autogenous Vaccines Market by End User
The global autogenous vaccines market finds its major end user in livestock farming companies, veterinary clinics and hospitals, veterinary research institutes. Livestock farming companies is likely to gain major market share during the estimated forecast period. The autogenous vaccines are mostly used in Livestock farming companies as the market have gain significant attention for various products of livestock. Besides, the autogenous vaccines improve the passive immunity mechanism in animals that enhances their immune response towards a particular disease. Veterinary clinics and hospitals are use autogenous vaccines but net volume used by them is comparatively low as compared to livestock farming companies.
Autogenous Vaccines Market by Geography
Geographically, North America dominated the global Autogenous Vaccines market due to rise in livestock associated diseases like dermatitis, sinusitis, otitis externa, pharyngitis etc. & use of custom autogenous vaccines for the treatment of these diseases. Also factors such as increase in demand of livestock related products like egg, cheese, milk & various other dairy products in the market, technological advancements in the region along with increase in number of major & minor players in North America followed by their key mergers, acquisitions & partnerships along with new product approvals from regulatory bodies will contribute for North America to be a major region in the market. Asia pacific registered for the fastest growth in CAGR particularly due to rise in incidence of livestock associated diseases. China in APAC captured largest market share in autogenous vaccines market due to increase in the use of animal vaccines in the region.
Competitive Landscape Analysis
The competitive landscape analysis of autogenous vaccines market is certainly based range of market players operating in the healthcare market with increasing demand for production of autogenous vaccines. Besides, number of market players offered wide range of products for different end user in various geographic locations. The market has major competitive analysis based on new product launches as well as other developments.
The key players studied in market are Newport Laboratories, Inc., Elanco Animal Health, Vaxxinova, Hygieia Biological Laboratories, Phibro Animal Health Corporation, Agrilabs (Huvepharma Inc.), Ceva Sante Animale, Chapul Cricket Protein, ACE Laboratory Services, Zoetis Inc Mealworms Inc.
Recent Development:
October 2021: Vaxxinova announced that it has purchased Newport Laboratories, a company that manufactures custom-made vaccines for swine and cattle, from Boehringer Ingelheim. About 100 people work at Newport Laboratories in Worthington, Minn. They help veterinarians and livestock producers address animal health issues through diagnostic testing and production of autogenous, or custom-made, vaccines.
March 2021: The Elanco Animal Health company has launched poultry autogenous vaccine. Autogenous vaccines are an important poultry industry tool, providing an option to customize your vaccine program based on field challenges rather than relying solely on what commercial vaccines can provide for protection.
August 2019: Agreement to acquire Bayer AG's animal health business by Elanco Animal Health in is one of the major acquisitions in this space. This strategic move will help Elanco Animal Health enhance its market position.
March 2018: Apiam acquired Passionate Vetcare, a regional veterinary clinic in the north west of Bendigo, to support the opening of Apiam’s Bendigo Emergency & Referral Centre for servicing in the Central Victorian region.
January 2018: Huvepharma has announced its acquisition of AgriLabs in a move that will expand the U.S. presence of the global animal health and nutrition company and speed commercialization of their biologic solutions for animal health. The acquisition includes AgriLabs product lines including Colostrx CS and Colostrx CR; I-Site XP, MpB Guard and Pulmo-Guard PH-M vaccines; the VetGun insecticide delivery system; and AgriLabs' custom vaccines business. In addition, the acquisition also includes Antelope Valley Bios, a contract manufacturing business; and the VaxLiant portfolio of novel adjuvants - all based in Lincoln, Nebraska.
